Aytu BioPharma, Inc. (AYTU) — Financial statements
Income statement, balance sheet, and cash flow for Aytu BioPharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 66↑1.8% | 65↓39.3% | 107↑11.1% | 97↑47.3% | 66 | |
| Cost of Revenue | 21↑27.4% | 16↓60.4% | 41↓12.1% | 46↑27.3% | 36 | |
| Gross Profit | 46↓6.6% | 49↓26.4% | 67↑32.5% | 50↑72.2% | 29 | |
| Operating Expenses | ||||||
| R&D Expenses | 1↓52.1% | 3↓32.4% | 4↓67.7% | 13↑125.2% | 6 | |
| General & Administrative Expenses | 17↓12.9% | 20↓30.3% | 29↓8.1% | 31↑22.2% | 26 | |
| Selling & Marketing Expenses | 21↓5.3% | 22↓46.7% | 41↑7.1% | 39↑27.7% | 30 | |
| SG&A Expenses | 38↓8.9% | 42↓40.0% | 70↑0.3% | 70↑25.2% | 56 | |
| Other Expenses | 14↑140.6% | 6↓38.7% | 10↓87.7% | 78↑191.5% | 27 | |
| Operating Expenses | 54↑5.9% | 51↓39.5% | 84↓47.8% | 160↑81.9% | 88 | |
| Total Costs & Expenses | 74↑11.1% | 67↓46.4% | 124↓39.7% | 207↑65.9% | 125 | |
| Operating Results | ||||||
| Operating Income | -8↓392.0% | -2↑90.7% | -17↑84.5% | -110↓86.7% | -59 | |
| Depreciation & Amortization | 5↓20.0% | 7↓23.7% | 9↓13.1% | 10↑10.3% | 9 | |
| EBITDA | -5↓431.8% | 1↑143.0% | -3↑88.3% | -28↑3.7% | -29 | |
| EBIT | -10↓88.8% | -5↑56.0% | -12↑68.3% | -38↑0.4% | -38 | |
| Interest & Other Income | ||||||
| Net Interest Income | -4↑22.7% | -5↑3.4% | -5↑96.6% | -147 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.01 | 0.00 | |
| Interest Expense | 4↓22.7% | 5↓3.4% | 5↓96.6% | 147 | 0.00 | |
| Non-Operating Income | 2↓40.6% | 4↑174.9% | -5↑93.1% | -72↓248.1% | -21 | |
| Other Income / Expenses | -6↑32.7% | -9↓62864.3% | 0.01↓98.6% | 1↑21.1% | 0.84 | |
| Income Before Tax | -14↓32.4% | -10↑39.1% | -17↑84.3% | -109↓87.6% | -58 | |
| Income Tax Expense | 0.44↓79.6% | 2 | 0.00↑100.0% | -0.11↓142.5% | 0.26 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -14↓13.3% | -13↑26.6% | -17↑84.3% | -109↓86.6% | -58 | |
| Net Income from Discontinued Operations | 0.62↑118.7% | -3 | 0.00 | 0.00 | 0.00 | |
| Net Income | -14↑14.4% | -16↑7.1% | -17↑84.3% | -109↓86.6% | -58 | |
| Bottom-Line Net Income | -14↑14.4% | -16↑7.1% | -17↑84.3% | -109↓86.6% | -58 | |
| EPS (Basic) | -2.16↑24.5% | -2.86↑44.0% | -5.11↑93.1% | -74.01↓6.3% | -69.60 | |
| EPS (Diluted) | -2.16↑24.5% | -2.86↑44.0% | -5.11↑93.1% | -74.01↓6.3% | -69.60 | |
| Weighted Average Shares | 6↑13.4% | 6↑65.8% | 3↑127.2% | 1↑75.0% | 0.84 | |
| Weighted Average Diluted Shares | 6↑13.4% | 6↑65.8% | 3↑127.2% | 1↑75.0% | 0.84 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.